Diabetes mellitus and platelet function after administration of aspirin and a single 600 mg dose of clopidogrel

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 12, 2006, Pages 2566-2568

  Sibbing, D ^a   von Beckerath, O ^a   Schomig A ^a   Kastrati, A ^a   von Beckerath, N ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; COLLAGEN; FIBRINOGEN RECEPTOR; INSULIN; ORAL ANTIDIABETIC AGENT; PADGEM PROTEIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE;

ADULT; AGED; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET THERAPY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOFLUORESCENCE; KOLMOGOROV SMIRNOV TEST; MAJOR CLINICAL STUDY; MALE; NORMAL DISTRIBUTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SINGLE DRUG DOSE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADENOSINE DIPHOSPHATE; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; BLOOD PLATELETS; COLLAGEN; CORONARY ARTERIOSCLEROSIS; DIABETES COMPLICATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; RECEPTORS, THROMBIN; THROMBOSIS; TICLOPIDINE;

EID: 33750996747     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.02183.x     Document Type: Article

References (16)

1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-81.
2. Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury RT, Davis BR, Holmes Jr DR. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: A report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2004; 109: 476-80.
3. Colwell JA, Nesto RW. The platelet in diabetes: Focus on prevention of ischemic events. Diabetes Care 2003; 26: 2181-8.
4. Halushka PV, Rogers RC, Loadholt CB, Colwell JA. Increased platelet thromboxane synthesis in diabetes mellitus. J Lab Clin Med 1981; 97: 87-96.
5. Winocour PD, Laimins M, Colwell JA. Platelet survival in streptozotocin-induced diabetic rats. Thromb Haemost 1984; 51: 307-12.
6. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001; 24: 1476-85.
7. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Jimenez-Quevedo P, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Costa MA, Bass TA, Macaya C. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54: 2430-5.
8. Sagel J, Colwell JA, Crook L, Laimins M. Increased platelet aggregation in early diabetes mellitus. Ann Intern Med 1975; 82: 733-8.
9. Calverley DC, Hacker MR, Loda KA, Brass E, Buchanan TA, Tsao-Wei DD, Groshen S. Increased platelet Fc receptor expression as a potential contributing cause of platelet hypersensitivity to collagen in diabetes mellitus. Br J Haematol 2003; 121: 139-42.
10. Steinhubl SR, Berger PB, Mann III JT, Fry ET, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002; 288: 2411-20.
11. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US. Platelet reactivity in patients and recurrent events post-stenting: Results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46: 1820-6.
12. Müller I, Besta F, Schulz C, Massberg S, Schömig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 783-7.
13. Müller I, Seyfarth M, Rudiger S, Wolf B, Pogatsa-Murray G, Schömig A, Gawaz M. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001; 85: 92-3.
14. von Beckerath N, Taubert D, Pogatsa-Murray G, Schömig E, Kastrati A, Schömig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (Intracoronary stenting and antithrombotic regimen: Choose between 3 high oral doses for immediate clopidogrel effect) Trial. Circulation 2005; 112: 2946-50.
15. Mehilli J, Kastrati A, Schühlen H, Dibra A, Dotzer F, von Beckerath N, Bollwein H, Pache J, Dirschinger J, Berger PB, Schömig A. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004; 110: 3627-35.
16. Kastrati A, Mehilli J, Schühlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ, Bollwein H, Volmer C, Gawaz M, Berger PB, Schömig A. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004; 350: 232-8.